Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 08:00 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100, a...
October 16, 2025 08:00 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Company underscores clinical execution and confirms advanced negotiations underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE...
September 10, 2025 16:05 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced...
September 03, 2025 08:00 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and...
August 18, 2025 08:00 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Provides Corporate Update

-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory...
August 13, 2025 07:30 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced...
July 16, 2025 08:05 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements

PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced...
July 09, 2025 08:05 ET | Source: Lixte Biotechnology Holdings, Inc.

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings,...
July 08, 2025 16:05 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a...
July 02, 2025 16:05 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a...